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patterns of distant metastases among rectal
cancer patients post curative-intent surgery
without neoadjuvant therapy
Jy Ming Chiang1,2*, Pao Shiu Hsieh1, Jinn Shiun Chen1, Reiping Tang1, Jeng Fu You1 and Chien Yuh Yeh1Abstract
Background: Rectal cancer patients have a higher incidence of pulmonary metastases than those with colon cancer.
This study aimed to examine the effects of rectal cancer level on recurrence patterns in rectal cancer patients.
Methods: Patients with T3/T4 rectal cancers who underwent surgery between 2002 and 2006 were recruited in this
study. All the patients were followed up on until death. Recurrence patterns and survival rates were calculated in
relation to clinical variables.
Results: There were 884 patients were enrolled in this study. Patients with low-rectal cancer had significantly worse
five-year overall survival (OS) and disease-free survival (DFS) rates (47.25% and 44.07%, respectively) than patients with
mid-rectal (63.46% and 60.22%, respectively) and upper-rectal cancers (73.91% and 71.87%, respectively). The level of
the tumor (P <0.001), nodal status (P <0.001), tumor invasion depth (P <0.001), and tumor differentiation (P = 0.047,
P = 0.015) significantly affected the surgical outcomes related to OS and DFS in the univariate and multivariate analyses.
Furthermore, the level of the rectal cancer was a significant risk factor (hazard ratio 1.114; 95% CI, 1.074 to 1.161;
P <0.001) for local recurrence, lung metastases, bone metastases, and systemic lymph node metastases. Significantly
higher incidence rates of bone (53.8%) and brain metastases (22.6%) after initial lung metastases rather than initial liver
metastases (14.8% and 2.9%, respectively) were also observed.
Conclusions: For rectal cancer patients who underwent surgical resection, the rectal cancer level significantly affected
surgical outcomes including rates and patterns of distant metastases.Background
Over the past two to three decades, total mesorectal exci-
sion [1] and neoadjuvant chemoradiation therapy have
been widely adopted to reduce local recurrence [2] and
improve the surgical outcome of rectal cancer. Unfortu-
nately, most studies have not been able to show any sig-
nificant improvement in survival because the frequency of
distant metastases remained high [2-5]. Moreover, patients
with distal rectal cancer who underwent abdominoperi-
neal resection (APR) had worse oncological outcomes
than those who underwent anterior resection [6]. These* Correspondence: jmjiang1234@yahoo.com.tw
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unless otherwise stated.data raised the possibilities that low-rectal cancer pos-
sesses a distinct biological behavior or that extended APR
might require a more radical excision [7,8].
Previous reports have shown that rectal cancer pa-
tients have a much higher incidence of synchronous and
metachronous pulmonary metastases than those with
colon cancer [9-11]. Tan et al. [9] reported a 12% versus
6% rate of synchronous lung metastases for primary rec-
tal cancer compared with primary colon cancer. Simi-
larly, Mitry et al. [10] demonstrated that compared with
colon cancer, rectal cancer showed a 2.8-fold increase
(16.7% versus 7.5%, respectively) in the five-year cumula-
tive rate of synchronous lung metastases and a 2.63-fold
increase (9.1% versus 4.1%, respectively) in the rate of
metachronous lung metastases. Some clinicopathological
factors such as nodal status and tumor invasion depthLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in these studies [9-12]. However, the impact of the rectal
cancer level on local recurrences or distant metastases
remains unknown.
Here, we retrospectively analyzed the surgical outcomes
of rectal cancer patients who did not undergo neoadjuvant
chemoradiation therapy to characterize the rates and pat-




The database of the Colorectal Cancer Registry of the
colorectal surgery section in Chang Gung Memorial
Hospital (CGMH) was retrospectively reviewed for this
study. This registry was first established in 1985 and a
revised data record form was implemented in 1995. The
data collected included a detailed family history, demo-
graphic variables, preoperative evaluation, operation re-
cords, and postoperative follow-ups. The extent of the
cancer at the time of diagnosis was classified according
to the American Joint Committee on Cancer TNM sta-
ging system and Astler-Coller modified Dukes’ staging
system after surgery, with a review of the pathologic spe-
cimen and investigation of distant metastases. Tumor lo-
cations were classified according to the International
Classification of Diseases. The status at follow-up was up-
dated every year for the surviving patients. All the data
were recorded by surgical nursing specialists on a stan-
dardized form through patient interviews and from clinical
and pathological records. All the data were confirmed by
one of the authors (RP Tang or DF You) before being
translated into a numeric code and keyed into the com-
puter by a registry staff member (SN Lin). Follow-up data
were added annually by reviewing patients’ records on
medical charts. A telephone interview or mailed question-
naire was used if a patient’s medical records were not
available. The study was approved by the Institutional
Review Board of CGMH.
The records of all the patients with rectal cancers
who underwent surgery between 1 January 2002, and
31 December 2006 were retrieved. Demographic and
clinical variables were recorded including sex, age,
tumor histological grade, tumor location, tumor level
(distances from the anal verge) for rectal cancer, lymph
node status, operation morbidity and mortality, and
follow-up status. The tumors were graded on the basis
of the World Health Organization classification and
were staged by TNM classification.
Distal, middle, and upper-rectal cancers were defined as
tumors located less than 5.1, 5.1 to 10, and 10.1 cm or
more above the anal verge. Preoperative staging was per-
formed by physical examination, rigid sigmoidoscopy, and
colonofiberscopy. Endorectal ultrasound was sometimesrequired for tumors closer than 10 cm from the anal verge.
Routine chest to abdominal computerized tomography
scans (CT) were performed to survey distant metastases.
Follow-up
After colorectal tumor resection, the patients were en-
rolled in a follow-up program that involved outpatient
visits every three to four months for the first two post-
operative years, with physical examination and carci-
noembryonic antigen tests. A chest X-ray, abdominal
sonography or computer-assisted tomography scan, and
colonoscopy were performed every one to three years after
the operation and whenever necessary. All the patients
were followed up on until death or January 2012, which-
ever came first. Recurrence was histologically confirmed
by biopsy, reoperation, imaging study, elevation of tumor
marker, or a combination of these. The index date for the
determination of survival time was defined as the date of
colorectal cancer surgery. Disease-free survival time was
the interval between surgery and the date of recurrence.
Overall survival was calculated between date of surgery
and last department contact (scheduled follow-up, mailed
response, or telephone contact) or patient death (verified
by medical record or death certificate).
Statistical analyses
The data were entered into Excel 2000 (Microsoft
Corporation, Redmond, Washington, United States)
and analyzed using the Statistical Package for the Social
Sciences (release 13.0; SPSS Inc., Chicago, Illinois, United
States). The chi-squared test for trends or the Fisher exact
test was used whenever appropriate. Overall survival (OS)
and disease-free survival (DFS) rates were calculated using
the Kaplan-Meier method, and the log-rank test was used
to compare the significance of the differences between the
groups. Cox proportional hazards regression was used
to assess the individual contribution of the factors asso-
ciated with recurrences. All the variables that were sig-
nificant in the univariate analysis were entered into a
multivariate analysis. All the tests were two-sided and
all the results are presented with their hazard ratios
(HR) and 95% confidence intervals (CI). Statistical sig-
nificance was set at P <0.05.
Results
Patients and clinicopathological features
From 1 January 2002 to 31 December 2006, 1810 pa-
tients were found with rectal adenocarcinoma and
underwent resection at the CGMH, including 58 Tis,
144 T1, 292 T2, 766 T3, 516 T4, and 34 T staging-
unknown patients. From the 1282 patients with T3 or T4
rectal cancers, 279 had synchronous distant metastases. Of
the remaining 1003 T3/T4 patients without synchronous
distant metastases, 119 accepted preoperative neoadjuvant
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2500 cGy at 500 cGy 5 times) or long-course chemoradia-
tion therapy (CCRT; total dose 5040 cGy at 180 cGy 28
times, combined with 5-Fu chemotherapy) based on the
surgeon’s advice. These patients were excluded and the
remaining 884 patients were enrolled in this study. Surgical
resection was performed according to the principle of total
mesorectal excision. The mean follow-up period was
77.8 months (range: 20.0 to 154 months, standard devi-
ation: 32.7 months).
The clinicopathological characteristics of these patients
according to the level of the rectal cancer (distal rectum, 0
to 5 cm above the anal verge; mid-rectum, 5.1 to 10 cm
above the anal verge; and upper rectum, 10.1 to 15 cm
above the anal verge) are summarized in Table 1. No sig-
nificant differences were observed in these features in
terms of rectal tumor level.
Treatment outcomes
Surgical outcomes including OS and DFS were shown to
be related to the level of the rectal cancer (Table 2). Sig-
nificantly worse one, three, and five-year OS and DFS
rates were observed for the distal rectum (88.87, 59.33,
and 47.25%, and 66.93, 47.39, and 44.07%, respectively)
and mid-rectum (94.86, 78.21, and 63.46%, and 84.04,
67.31, and 60.22%, respectively) than for the upper rec-
tum (94.46, 81.41, and 73.91%, and 86.83, 75.11, and
71.87%, respectively).
The results of the univariate analyses of the clinicopath-
ological features as prognostic factors for OS and DFS
were performed and are shown in Table 3. The results of
the multivariate analysis for significant prognostic factors
from the univariate analyses are shown in Table 4. NodalTable 1 Clinicopathological features of patients with rectal ade
Location of the tumor above the anal verge (cm)
Total number of patients with tumors at different locations
Number of female patients (%) 6
Number of male patients (%) 5











N2 3status (P <0.001), tumor invasion depth (P <0.001), tumor
differentiation (P = 0.047, P = 0.015), and rectal cancer
level (P <0.001) were significant factors affecting OS and
DFS in the univariate and multivariate analyses after
adjusting for age and sex.
Risk of recurrences related to location of rectal cancers
The risk of local recurrence or different distant metastases
according to the location of the rectal cancer was further
analyzed and the results are summarized in Table 5. The site
shown in this table indicated as the site of recurrence refers
to either local recurrence or distant metastases detected
during the follow-up period. In this study, isolated recur-
rence occurred in 167 patients (44%) and multiple recur-
rences (present in two or more organs at the same time
during follow-up) were discovered among 209 patients
(55%). The location of the rectal cancer was found to be a
significant risk factor for local recurrence, lung metastases,
bone metastases, and systemic lymph node metastases. For
example, lung metastasis was higher in distal rectal cancer
and mid-rectal cancer than in upper-rectal cancer (mid-rec-
tal cancer: HR, 1.760; P = 0.001; and low-rectal cancer: HR,
3.187; P <0.001). In other words, the risk of lung metastases
was more than three times higher for the distal rectum than
for the upper rectum (Table 5). In general, as the distance of
the rectal cancer relative to the anal verge decreased,
the HR for recurrences significantly increased (HR, 1.114;
95% CI, 1.074 to 1.161; P <0.001 for each 1 cm difference).
Sequential metastases after local recurrence, lung, and
liver metastases
Since local, liver, and lung were the three most common
sites of recurrences, the rates and patterns of sequentialnocarcinoma involving different locations along the rectum
0-5 cm 5.1-10 cm 10.1-15 cm
117 331 436
1 (52.14%) 151 (45.62%) 192 (44.04%)
6 (47.86%) 180 (54.38%) 244 (55.96%)
± 14 (30-96) 64 ± 14 (30-90) 65 ± 13 (24-95)
11 (9.40%) 32 (9.67%) 42 (9.63%)
6 (82.05%) 285 (86.10%) 375 (86.01%)
10 (8.55%) 14 (4.23%) 19 (4.36%)
3 (70.94%) 221 (66.67%) 259 (59.40%)
4 (29.06%) 110 (33.23%) 177 (40.60%)
3 (45.30%) 147 (44.41%) 194 (44.50%)
7 (23.08%) 84 (25.38%) 138 (31.65%)
7 (31.62%) 100 (30.21%) 104 (23.85%)
Table 2 Overall survival and disease-free survival of patients with rectal adenocarcinoma involving different locations along the rectum
Tumor location Total patient no. Overall survival Disease-free survival
1 year (%) 3 years (%) 5 years (%) HR 95.0% CI P 1 year (%) 3 years (%) 5 years (%) HR 95.0% CI P
10.1-15 cm 436 94.46 81.41 73.91 1 86.83 75.11 71.87 1
5.1-10 cm 331 94.86 78.21 63.46 1.263 1.004-1.589 0.046 84.04 67.31 60.22 1.508 1.177-1.932 0.001




















Table 3 Univariate analysis of the clinicopathological features as prognostic factors for overall survival and
disease-free survival
Overall survival Disease-free survival
Variables HR 95.0% CI for HR P HR 95.0% CI for HR P
Age 1.024 1.015-1.033 <0.001 0.995 0.987-1.004 0.305
Sex
Female 1 - - 1 - -
Male 1.237 1.003-1.525 0.047 0.956 0.766-1.193 0.689
Location along the rectum
10.1-15 cm 1 1
5.1-10 cm 1.263 1.004-1.589 0.046 1.508 1.177-1.932 0.001
0-5 cm 2.092 1.571-2.786 <0.001 2.548 1.876-3.460 <0.001
TMN_T
T3 1 - - 1 - -
T4 1.436 1.166-1.770 0.001 1.606 1.285-2.006 <0.001
TMN_N
N0 1 - - 1 - -
N1 1.543 1.186-2.008 0.001 2.155 1.599-2.904 <0.001
N2-N3 2.435 1.904-3.114 <0.001 3.751 2.847-4.941 <0.001
HG
Well 1 - - 1 - -
Mod 1.039 0.732-1.475 0.830 1.313 0.871-1.979 0.193
Poor 2.194 1.313-3.669 0.003 2.879 1.644-5.043 <0.001
Table 4 Multivariate analysis of significant prognostic factors identified by univariate analysis
Overall survival Disease-free survival
Variables HR 95.0% CI for HR P HR 95.0% CI for HR P
Age 1.026 1.017-1.035 <0.001 - - -
Sex
Female 1 - - - - -
Male 1.260 1.019-1.558 0.033 - - -
Location along the rectum
10.1-15 cm 1 1
5.1-10 cm 1.315 1.044-1.657 0.020 1.570 1.224-2.014 <0.001
0-5 cm 2.284 1.69-3.03 <0.001- 2.780 2.038-3.792 <0.001
TMN_T
T3 1 - - 1 - -
T4 1.480 1.195-1.835 <0.001 1.593 1.268-2.001 <0.001
TMN_N
N0 1 - - 1 - -
N1 1.693 1.296-2.211 <0.001 2.194 1.623-2.966 <0.001
N2-N3 2.454 1.902-3.166 <0.001 3.377 2.543-4.485 <0.001
HG
Well 1 - - 1 - -
Mod 0.891 0.622-1.287 0.530 1.056 0.695-1.604 0.798
Poor 1.710 1.008-2.899 0.047 2.044 1.152-3.627 0.015
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Table 5 Correlation of the risk of local recurrence and patterns of distant metastases with the location of the
adenocarcinoma along the rectum
Adenocarcinoma location 10.1-15 cm (n = 436) 5.1-10 cm (n = 331) 0-5 cm (n = 117)
Patient no. (%) HR 95% CI Patient no. (%) HR 95% CI P Patient no. (%) HR 95% CI P
Recurrence in patients/
Recurrence patterns
Local 36 (8.26) 1 - 50 (15.11) 1.885 1.23-2.89 0.004 23 (19.66) 2.786 1.65-4.70 <0.001
Lung 57 (13.07) 1 - 73 (22.05) 1.760 1.25-2.49 0.001 38 (32.48) 3.187 2.11-4.81 <0.001
Liver 58 (13.3) 1 - 45 (13.06) 1.012 0.69-1.49 0.951 12 (10.26) 0.832 0.45-1.55 0.563
Bone 15 (3.44) 1 - 23 (6.95) 2.090 1.09-4.01 0.026 13 (11.11) 4.043 1.92-8.51 <0.001
Brain 6 (1.38) 1 - 8 (2.42) 1.819 0.63-5.24 0.268 4 (3.42) 3.136 0.88-11.13 0.077
Carcinomatosis 8 (1.83) 1 - 9 (2.72) 1.494 0.58-3.87 0.409 5 (4.27) 2.649 0.87-8.10 0.088
Systemic LN 15 (3.44) 1 - 31 (9.37) 2.788 1.51-5.17 0.001 17 (14.53) 5.046 2.52-10.11 <0.001
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summarized and compared in Table 6. During the follow-
up period isolated metastases were found among 140 pa-
tients, including 53 lung metastases, 42 liver metastases,
and isolated local recurrence in 45 patients. Multiple
organ metastases were found in 176 patients; sequential
metastases after initial local recurrence, initial lung, or ini-
tial liver metastases are shown in Table 6. Significantly
higher rates of bone (53.8%) and brain metastases (22.6%)
were observed after initial lung metastases than after ini-
tial liver metastases (14.7% and 2.9%, respectively) and ini-
tial local recurrence (10.7% and 3.6%, respectively). In
addition, higher lung metastases (78.6%) were found after
initial liver recurrence. A significant difference in the
mean time that brain metastases were detected after liver
(732 days), lung (345 days), and local recurrence (398 days,
P <0.01) were also observed. Furthermore, brain metasta-
ses were found to be significantly higher (22.6% versus
3.6% and 2.9%, respectively) after lung metastases. It is in-
teresting that liver metastases (15.4%) were also detected
after lung metastases, with a mean delayed time of
272 days. Local recurrences were detected after liver and
lung metastases (11.5% and 10.7%, respectively).Table 6 Sequential metastases after lung and liver metastase
Local first L
Number of patients (%) Number
Solitary 45 Solitary
Multiple 68 (100) Multiple
Multiple Organs Lung 32 (47.0) Local
Liver 23 (33.9) Liver
Bone 10 (14.7) Bone
Brain 2 (2.9) Brain
Carcinomatosis 7 (10.3) Carcinomato
Systemic LN 22 (32.3) Systemic LDiscussion
Here, we have demonstrated that in addition to nodal
status, tumor invasion depth, and tumor differentiation,
location of the rectal cancer also significantly affects the
surgical outcome (OS and DFS) of patients who did not
undergo neoadjuvant chemoradiation therapy. Com-
pared with those with upper-rectal cancer, patients with
distal and mid-rectal cancers were more likely to have
distant metastases, including lung, bone, and systemic
lymph node metastases. A significant increase in the fre-
quency of developing lung metastases was observed for
distal and mid-rectal cancers (3.18-fold and 1.76-fold, re-
spectively). Similarly, significant increases in the fre-
quencies of bone metastases (4.04-fold and 2.09-fold for
distal and mid-rectum, respectively) and systemic lymph
node metastases (5.04-fold and 2.78-fold for distal and
mid-rectum, respectively) were also observed. To our
knowledge, this is the first report revealing the influence
of rectal cancer location on distant metastases patterns
among patients without CCRT, and the findings presented
here may impact several aspects of clinical practice.
First, our data may influence the preoperative staging
protocol and postoperative follow-up strategy. Somes
ung first Liver first
of patients (%) Number of patients (%) P
53 Solitary 42
52 (100) Multiple 56 (100)
6 (11.5) Local 6 (10.7)
8 (15.4) Lung 44 (78.6)
28 (53.8) Bone 6 (10.7) 0.001
12 (22.6) Brain 2 (3.6) 0.010
sis 6 (11.5) Carcinomatosis 3 (5.4) 0.185
N 16 (30.7) Systemic LN 18 (32.1) 0.120
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tive chest CT’s and indicate that it does not influence
therapeutic strategy in colorectal cancer patients. This is
because interpretation of the nature of pulmonary le-
sions is not always easy and only a small proportion of
these lesions are actually malignant [13]. However, other
studies have shown that a chest CT should be recom-
mended as a routine staging method at least for low-
and mid-rectal cancers because of their higher rates of
lung metastases [9-11]. In addition, a preoperative chest
CT is useful for the early detection of pulmonary metas-
tases as a baseline study for abnormal lung nodules [12].
Currently, a wide variety of imaging methods are avail-
able for colorectal cancer staging, thus, selection based
on the particular organs involved and high-risk sites
may be important.
Second, our data might provide a baseline reference for
comparisons of treatment outcomes with and without
neoadjuvant chemoradiation therapy. Many previous neo-
adjuvant CCRT studies have shown that although reduced
local recurrence could be achieved, survival was not sig-
nificantly improved because the frequencies of distant me-
tastases remained high [2-5]. Furthermore, a recent report
showed that pulmonary recurrence predominates after
combined chemoradiation therapy and surgical resection
for locally advanced rectal cancer patients [14]. The study
demonstrated that post-resection rectal cancer without
neoadjuvant chemoradiation showed a higher risk of lung
metastases for lower-lying rectal cancers, similar to the
findings presented here. Thus, the ratio of different levels
of rectal cancer patients included in different studies may
significantly affect the observed recurrence patterns and
rates in the same way that T or N stages do. Based on
these results, the prevention of systemic metastases should
be emphasized during the introduction of more effective
neoadjuvant chemotherapy. This is especially important
for subgroups of patients with one or more risk factors
such as low- and mid-rectal cancers, high degrees of inva-
sion of the bowel wall, and involvement of local lymph
nodes.
The significant increase of distant metastases for distal
and mid-rectal cancers may be multifactorial rather than
related to an increase in local recurrence, as only 17.7%
(32 of 181 patients) of lung metastases were followed by
local recurrence with a mean time of 271 days (Table 6).
These increased lung and other distant metastases may
be explained by existing anatomic reasons. Anatomically,
the rectum is approximately 15 cm in length commen-
cing from the sacral promontory to the anorectal ring.
The rectum is usually described as having three segments:
an upper, a middle, and a lower. Lymphatic drainage ac-
companied with blood supplies to these three segments
are from the superior, middle, and inferior rectal artery
and vein. The superior rectal vein is drained into theinferior mesenteric vein and then to the portal system,
while the inferior rectal vein drains into the common iliac
vein and to the inferior vena cava, and middle rectum
drainage may be both cephalad to the inferior vein and lat-
eral to the internal iliac vein. Therefore a distal rectal
tumor may easily metastasize initially to the lungs because
the inferior rectal vein drains into the inferior vena cava,
bypassing the portal venous system. Basically, distant me-
tastasis of cancer is presumed to occur via lymphatic or
vascular drainage routes, and the liver is the first organ of
the reticuloendothelial system that would allow for the ini-
tial dissemination of colon and upper-rectal cancers enter-
ing through the portal vein. Thus, the liver is clinically
reported to be the most common site of distant metasta-
ses. However, if the drainage of distal or mid-rectal cancer
cells were via the inferior and middle rectal vein into the
inferior vena cava (systemic circulation) rather than drain-
age into the portal system (such as the colon and upper
rectum via the inferior mesenteric vein), then the metasta-
sis patterns might differ based on the location of the rectal
cancer. Unfortunately, very few papers have described the
existing anatomic factors that significantly affect metasta-
sis variances; for example, for lower rectal cancer, systemic
venous circulation plays a more important role in the
metastatic process.
Distant metastases basically follow mechanical vascu-
lar spreading, a ‘cascade’ process of metastasis of metas-
tases described by Viadana et al. [15]. This process
might be also affected by a process described by the
‘seed and soil’ theory [16], which indicates that delivery
of cancer cells to different organs varies in efficiency
[16,17]. However, the seed and soil theory is not mutu-
ally exclusive with hemodynamic theories [17]. In this
study, our data highlights the importance of vascular pa-
rameters related to the metastatic pattern. Most cases
(156 of 176, 88.6%) followed the theory of mechanical
vascular spreading (Table 6). However, the findings that
11.4% (20 of 176 cases; 6 lung metastases followed by
local recurrence, 8 lung metastases followed by liver me-
tastases, and 6 liver metastases followed by local recur-
rence; Table 6) may indicate variable efficiencies in cancer
cell delivery to different organs. This result may point to
the fact that site and growth rate in different organs may
be two independent processes for metastases. In summary,
our study emphasizes that mechanical vascular-spreading
theories predominantly determine the disseminating site
of metastases, whereas the rate of metastasis growth may
also be controlled by other factors such as the seed and
soil theory.
This study provides important insight into the effects of
rectal cancer location on recurrence patterns; however,
this study had some limitations. First, we did not have data
on the distance of the circumferential resection margin in
our database for this study period (2002 to 2006). Our
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tial resection margin status. This is recorded in the hist-
ology report of the tumor specimen, which is prepared by
a pathologist. However, the high local recurrence rate for
low-lying tumors may be related to the high rates of a
positive circumferential resection margin. Second, during
the study period, we did not adopt the cylindrical excision
technique by Holm [18]. We may well consider that this
technique will improve surgical outcomes for low-lying
rectal cancer in terms of local recurrence. However, to
what extent this technique contributes to distant metasta-
ses rates, such as the high rate of lung metastases, remains
unclear. Third, although T3/T4 rectal cancer patients with
or without lymph node involvement were included in this
retrospective study, preoperative neoadjuvant chemoradia-
tion therapy was not routinely applied, as this was not
adopted as a guideline in our hospital until 2007. During
the years 2002 to 2006, 119 patients who accepted pre-
operative neoadjuvant radiation therapy or CCRT based
on the individual surgeon’s preference were excluded from
this study. Fourth, not all diagnosed distant metastases in
this series were diagnosed through confirmed histological
or cytological examination results, thus some patients may
not have been differentially evaluated from those who had
other secondary primaries or just post-infective scarring.
Conclusions
In summary, the level of the rectal cancer significantly
affected surgical outcomes, including rates and patterns
of distant metastases for the patients who underwent
surgical resection. Lung, bone, and systemic lymph node
metastases significantly increased as the level of the rec-
tal cancer decreased.
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